US top court rejects generic drug labeling suits

WASHINGTON, June 23 (Reuters) - The U.S. Supreme Court ruled on Thursday that generic drug companies cannot be sued under state law over allegations that they failed to provide adequate label warnings about potential side effects.

The justices handed a victory to Israel's Teva Pharmaceutical Industries Ltd (TEVA.TA), Mylan Inc's (MYL.O) UDL Laboratories and Iceland-based Actavis Inc by overturning U.S. appeals court rulings that allowed such lawsuits. (Reporting by James Vicini, Editing by Gerald E. McCormick)